Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes

Heart

Volumn 102, Issue 24, 2016, Pages 1963-1968

  Resl, M ^a,b   Clodi, M ^b   Vila, G ^a   Luger, A ^a   Neuhold, S ^c   Wurm, R ^a   Adlbrecht, C ^a   Strunk, G ^d,e   Fritzer Szekeres, M ^a   Prager, R ^f   Pacher, R ^a   Hulsmann M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d TU DORTMUND UNIVERSITY   (Germany)

^e Fachhochschule Campus Wien   (Austria)

^f Hietzing Hospital Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; GDF15 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; AUSTRIA; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; HOSPITALIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; TIME FACTOR; UPREGULATION;

ADULT; AGED; AUSTRIA; BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TROPONIN T; UP-REGULATION;

EID: 84979583957     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308949     Document Type: Article

References (26)

1. Chang YT, Wu JL, Hsu CC, et al. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998-2009. Diabetes Care 2014; 37: 277-85
2. Coleman RL, Stevens RJ, Retnakaran R, et al. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30: 1292-3
3. Huelsmann M, Neuhold S, Strunk G, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 2008; 29: 2259-64
4. Bruno G, Landi A, Barutta F, et al. N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care 2013; 36: 2677-82
5. Clodi M, Resl M, Neuhold S, et al. A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol 2012; 19: 944-51
6. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013; 62: 1365-72
7. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310: 66-74
8. Eggers KM, Kempf T, Wallentin L, et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013; 59: 1091-8
9. Hillis GS, Welsh P, Chalmers J, et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 2014; 37: 295-303
10. Seliger SL, de Lemos J, Neeland IJ, et al. Older adults, "Malignant" left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). JACC Heart Fail 2015; 3: 445-55
11. Heringlake M, Charitos EI, Gatz N, et al. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients. J Am Coll Cardiol 2013; 61: 672-81
12. Widera C, Pencina MJ, Bobadilla M, et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem 2013; 59: 1497-505
13. Lok DJ, Klip IT, Lok SI, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013; 112: 831-7
14. Vila G, Riedl M, Anderwald C, et al. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011; 57: 309-16
15. Schindler K, Vila G, Hoppichler F, et al. The impact of type 2 diabetes on circulating adipokines in patients with metabolic syndrome. Obes Facts 2012; 5: 270-6
16. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2014; 114: 890-4
17. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-16
18. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21
19. Vila G, Resl M, Stelzeneder D, et al. Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol 2008; 105: 1741-5
20. Lazo M, Young JH, Brancati FL, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 2013; 62: 3189-93
21. Macia L, Tsai VW, Nguyen AD, et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS ONE 2012; 7: e34868
22. Ding Q, Mracek T, Gonzalez-Muniesa P, et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009; 150: 1688-96
23. Li J, Yang L, Qin W, et al. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus. PLoS ONE 2013; 8: e65549
24. Resl M, Vila G, Grimm G, et al. Effects of B-type natriuretic peptide on cardiovascular biomarkers in healthy volunteers. J Appl Physiol 2015; 118: 395-9
25. Felker GM, Ahmad T. Natriuretic peptides and primary prevention: the new world? J Am Coll Cardiol 2013; 62: 1373-5
26. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012; 125: 233-40